EU greenlights Novartis 3-in-1 hypertension pill
The European Commission has granted Novartis marketing authorization for Exforge HCT, a new 3-in-1 treatment for people with high blood pressure.
Exforge HCT combines in a once-daily single pill the efficacy of three widely prescribed blood pressure medications: the angiotensin receptor blocker valsartan (Diovan), the calcium channel blocker amlodipine, and the diuretic hydrochlorothiazide (HCT), according to the Basel, Switzerland-based company.
In the European Union, Exforge HCT is now indicated for substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of valsartan, amlodipine and HCT, taken either as three single-component formulations or as a dual-component and a single-component formulation, according to Novartis.
Exforge HCT combines in a once-daily single pill the efficacy of three widely prescribed blood pressure medications: the angiotensin receptor blocker valsartan (Diovan), the calcium channel blocker amlodipine, and the diuretic hydrochlorothiazide (HCT), according to the Basel, Switzerland-based company.
In the European Union, Exforge HCT is now indicated for substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of valsartan, amlodipine and HCT, taken either as three single-component formulations or as a dual-component and a single-component formulation, according to Novartis.